Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OV329 evaluation in adults with epilepsy and photoparoxysmal response
NL-OMON61431Phase 2Recruiting
- Sponsor
- Ovid Therapeutics
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of OV329 in epilepsy (2 arms), sponsored by Ovid Therapeutics. Primary endpoint: Change from baseline in standardized photosensitivity range. Started Aug 2026; status: recruiting.
02
Drugs
OV329
03
Conditions
epilepsy
Beyond the preview
Go deeper on NL-OMON61431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61431.